Chronic toxicity and/or oncogenicity studies were conducted in rats, mice, and dogs with the insect repellent DEET. DEET was mixed in the diet and administered to CD rats for two years at concentrations that corresponded to dosage levels of 10, 30 or 100 mg/kg/day for males and 30, 100, or 400 mg/kg/day for females; to CD -1 mice for 18 months at dosage levels of 250, 500, or 1000 mg/kg/day; and to dogs for one year, via gelatin capsules, at dosage levels of 30, 100, or 400 mg/kg/day. In the rodent studies, each group consisted of 60 animals of each sex, and two concurrent independent control groups, each containing 60 animals/sex were included in each study. Each group in the dog study consisted of four male and four female dogs and one control group was included in the study. Treatment-related effects were observed at the highest dose level in all three studies. For rats, the effects included decreases in body weight and food consumption and an increase in serum cholesterol in females only. In mice, the effects observed were decreases in body weight and food consumption in both sexes. The effects observed in dogs included increased incidences of emesis and ptyalism, and levels of transient reduction in hemoglobin and hematocrit, increased alkaline phosphatase (males only), decreased cholesterol, and increased potassium. One male dog in the high-dose group also exhibited ataxia, tremors, abnormal head movements, and/or convulsions on several occasions during the study. The highest no-observed-effect levels (NOELs) for rats, mice and dogs were determined to be 100, 500, and 100 mg/kg/day, respectively. No specific target organ toxicity or oncogenicity was observed in any of the studies.
N,N-diethyl-m-toluamide (DEET) is the principal active ingredient in most personal insect repellents. It is effective against a broad spectrum of insect pests including mosquitoes, biting flies and ticks. It was first developed and patented by the U.S. Army in 1946 for use by military personnel in insectinfested areas. It was later registered for use by the general population in 1957 (U.S. Environmental Protection Agency, 1980) . It is estimated that approximately 30% of the U.S. population uses a DEET-containing insect repellent product to repel biting insects.
In order to provide a comprehensive safety database and to maintain the worldwide registration of DEET, an extensive mammalian toxicology, data-development program was conducted by the major manufacturers and marketers of DEET (DEET Joint Venture) under the auspices of the Chemical Specialties Manufacturers' Association. This manuscript describes a two-year dietary toxicity and oncogenicity study in the CD rat, an 18-month dietary oncogenicity study in the CD -1 mouse, and a one-year dietary toxicity study in the beagle dog, which were part of this large data-development program.
Although the principal route of DEET exposure in humans is dermal, little or no toxicity can be produced in laboratory animals by this route of administration. Therefore, the oral route of administration was used in these studies in order to satisfy the criteria of evaluating toxicity at a maximum tolerated dose. Another important consideration for selecting the oral route of exposure is that data developed by this route can easily be extrapolated to potential dermal exposure and are amenable to use in human risk assessments. The oral route of administration also avoided the practical problems associated with repeated dermal administration of undiluted DEET and the skin irritation that may have been produced. Morflex Chemical Co. (Lot N61214-59401) . Purity of this mixture was determined to be Ն 98.3% (98.0% meta, 0.13% para, and 0.17 % ortho).
Animals and husbandry. CD (Sprague Dawley-derived) rats and CD-1 (Swiss outbred) mice were purchased from Charles River Breeding Laboratories, Inc., Portage, MI. Purebred beagle dogs were purchased from Ridglan Farms, Mt. Horeb, WI. Animals were housed individually in stainless steel cages in rooms designed to maintain appropriate environmental conditions for temperature, relative humidity and light cycle. Rats and mice were allowed continuous access to treated or control diet (Purina Certified Rodent Chow #5002). Each dog was offered untreated diet (Purina Certified Canine Chow #5007) twice daily for approximately one-hour immediately prior to dose administration. All animals were allowed tap water ad libitum. Dogs were given the opportunity to exercise at least 30 min per day, 3 days per week throughout the study.
Preparation and analyses of treated diets. Test diets for the rats and mice were prepared on an active-ingredient basis by direct addition of DEET to ground rodent chow. An initial concentrated premix was prepared to ensure homogeneous incorporation of the test substance. Test diets were prepared by appropriate dilutions of the concentrated premix with untreated rodent chow. Fresh test diet was prepared and offered to the animals each week. The homogeneity, stability and concentration of DEET in the treated diets were confirmed analytically. These analyses showed that the DEET was distributed homogeneously and was stable in the diets for at least 14 days, and that the diets contained the desired concentration of test material.
DEET was administered to dogs via gelatin capsules twice daily as a divided-dose regimen, immediately following the twice daily feeding periods. The 0.25 ounce (approximately 7 ml) gelatin capsules were prepared by placing the appropriate amount of undiluted DEET or control substance (white mineral oil) directly into the capsules. The volume of test or control substance added to each capsule was calculated based on the animal's most recent body weight. Fresh capsules were prepared weekly. The stability of undiluted DEET stored in gelatin capsules was demonstrated prior to the start of the study.
Dose level selection.
The dietary concentrations of DEET used for the rat combined chronic toxicity/oncogenicity study were based on the results of dietary dose range-finding studies conducted over 13 weeks and a dietary two-generation reproduction study. These studies demonstrated that the major effects of orally administered DEET were depressed food consumption and lower body-weight gains at dosage levels Ն 500 mg/kg/day, and renal lesions indicative of ␣2 globulin accumulation in male rats at dosage levels Ն 100 mg/kg/day. Based upon these findings, 400 mg/kg/day was chosen as the highest dietary dosage for females and 100 mg/kg/day for males.
In a 13-week, dose range-finding study conducted in mice, reduced body weight gain was observed at dosage levels Ն 3000 mg/kg/day, absolute and relative liver weights were increased at levels Ն 300 mg/kg/day and hepatocellular hypertrophy was observed at levels Ն 1000 mg/kg/day. Therefore, a dietary dosage of 1000 mg/kg/day was selected as the highest concentration for the 18-month mouse oncogenicity study.
In the case of the dogs, the preferred method of dose administration was dietary incorporation. However, refusal to consume the treated diets occurred during dose range-finding studies at dietary concentrations below which any toxic effects were observed, i.e., 3000 ppm (approximately 75 mg/kg/day). Subsequently, it was determined that dogs would tolerate higher dosages of DEET when it was administered in gelatin capsules given twice daily in equally divided doses, after eating. This dosage regimen also was considered to simulate more closely the slower and more even absorption patterns that humans experience when DEET is applied dermally than would single oral doses administered to fasted dogs. Under this dosage regimen, the daily dosage considered to be the maximum that could be tolerated by dogs in a chronic exposure situation was 400 mg/kg/day. At this level, ptyalism, unusual head movements, and decreases in body weight, food consumption, and cholesterol levels were observed in an eight-week dose range-finding study. Mid-and low-dose levels were selected for each species, with the intent of demonstrating no-observed-effect levels (NOELs) at the low-dose levels and the potential for observing some intermediate level of toxicity at the mid-dose levels. For rats, dietary concentrations corresponding to dose levels of 10, 30, and 100 mg/kg/day for males, and 30, 100, and 400 mg/kg/day for females were evaluated. For mice, dietary concentrations corresponding to dose levels of 250, 500, and 1000 mg/kg/day were evaluated in both sexes. Dogs were administered divided daily dosages of undiluted DEET in gelatin capsules at dose levels of 30, 100, and 400 mg/kg/day. Study design. The organization of animals and treatment groups for the chronic toxicity and oncogenicity studies is presented in Table 1 . The duration of treatment for rats was two years, for mice 18 months, and for dogs one year. Sixty animals/sex/group and two independent control groups were used in each of the rodent studies. In the dog study, four dogs/sex/group were used and one control group was included. Experimental evaluations in all studies included survival, clinical observations for signs of toxicity, body weight, food consumption, hematology, organ weights, and gross and microscopic pathology. Ophthalmology, clinical chemistry and urinalysis also were included in the rat and dog studies. Histopathology was conducted on a full set of tissues for rats and mice in the control and high-dose groups and for dogs in all groups. Lungs, livers, kidneys and gross lesions of rats and mice in the low-and mid-dose groups were also examined microscopically.
Statistical analyses.
In the rodent studies, the two control groups in each study were treated as independent entities for all statistical analyses. Data for continuous parametric variables were compared between the treatment and control groups by use of one-way analysis of variance (ANOVA). If ANOVA was not significant, no further test was performed; otherwise a Bartlett's test for homogeneity of variance was performed, as described by Steel and Torrie (1960) , followed by the appropriate pairwise comparisons. If the Bartlett's test was not significant, a Dunnett's t-test (Dunnett 1964 ) was used for the pairwise comparisons; otherwise, the Welch t-test (Neter and Wasserman 1974; Welch 1938 ) with a Bonferroni correction (Neter and Wasserman, 1974) was used. When nonparametric statistical tests were required, the rank transformation methods described by Conover and Iman (1981) were used. All pairwise comparisons were between treated and control groups. Statistical tests were conducted at the 0.05 and 0.01 levels of significance. Tumor-incidence data were analyzed as described by Huff et al. (1988) . Statistical procedures included the life-table test, the Hoel-Walburg "incidental tumor" test, Fisher's exact test, and the Cochran-Armitage trend test. Microscopic lesions in tissues from animals in the low-and mid-dose groups, examined only as a result of a gross finding, were not analyzed statistically.
In the dog study, parametric data were analyzed using Bartlett's test for homogeneity of variances, analysis of variance (1-way classification), and the appropriate t-test (for equal or unequal variances), as described by Steel and Torrie (1960) . Dunnett's multiple comparison tables (Dunnett 1964) or pairwise comparisons with a Bonferroni correction (Neter and Wasserman 1974) were used to determine the significance of differences. When nonparametric statistical tests were required, the rank transformation methods described by Conover and Iman (1981) were used. All statistical analyses were performed with p Յ 0.05 and p Յ 0.01 used as levels of significance.
FIG. 2.
Mean body weights of male (A) and female (B) rats. 
RESULTS

Chronic Toxicity/Oncogenicity Study in Rats
No treatment-related clinical signs of toxicity were observed, there was no effect on survival (Figs. 1A and 1B), nor were there any treatment-related effects in the parameters of ophthalmology (conducted pretest and at study termination), hematology, urinalysis (conducted during weeks 26, 52, 78 and 104), organ weights, or gross and microscopic pathology. Body weight and food consumption values for males were similar to one or both of the control groups, when compared to the treatment groups, throughout the study (body weight data presented in Fig. 2A ). Statistical decreases in body weight and body-weight gain were observed for females in the 400 mg/ Note. DOS ϭ died on study; SAC ϭ scheduled sacrifice; ٩ ϭ number of animals examined. Note. DOS ϭ died on study; SAC ϭ scheduled sacrifice; ٩ ϭ number of animals examined.
kg/day group throughout the study (Fig. 2B ). This decrease in body weight exceeded 10% compared to controls at several measurement intervals during the second year of the study. Average food consumption also was decreased for females at the 400 mg/kg/day dosage level compared to both control groups (data not shown). There were slight, statistically significant increases in cholesterol values for females in the 400 mg/kg/day dosage group at 6-, 12-and 18-month evaluations. These increased cholesterol values were considered to be consistent with an effect due to treatment (Table 2) . There were no neoplastic or nonneoplastic lesions observed for male or female rats in this study that were attributable to the administration of the test material. There was a slight numerical increase in the incidence of renal cell adenomas for males in the 10 mg/kg/day treatment group (3/60) compared to control groups (1/60 and 0/60). Renal cell adenomas were not observed for males in the 30-or 100-mg/kg/day treatment groups or for females in any treatment group. While renal cell adenomas are considered to be rare tumors (generally occurring at an incidence of less that 1%), the slight increase observed in this study was not considered to be related to the treatment with the test substance, based on a lack of doseresponse relationship and the presence of a renal cell adenoma in one control group male rat. A number of other microscopic observations were seen in both male and female rats across dosage groups (Tables 3 and 4) , which were considered to be spontaneous or naturally occurring and not related to the administration of the test material. Some of the more common findings included: vacuolar changes in the adrenal cortex, primarily in males; cystic degeneration in the adrenal cortex, primarily in females; cardiomyopathy, more common in males; chronic progressive neuropathy, more common in males; the occurrence of fibroadenomas and galactoceles in the female mammary gland; ovarian cysts; pituitary adenomas, slightly more common in females; ulcerative pododermatitis, especially in males; and uterine dilatation, cysts, and the presence of uterine polyps. Other spontaneous lesions typical for this age and strain of rat were observed occasionally. 
Mouse Oncogenicity Study
No treatment-related clinical signs of toxicity were observed, there was no effect on survival (Figs. 3A and 3B ), nor were there treatment-related effects on hematology (conducted during study weeks 52 and 79) or gross pathology. Statistically significant differences from control mean-body-weight values were noted frequently during weeks 16 to 78 for males at the 250 mg/kg/day dosage level, and for both males and females in the 500 and 1000 mg/kg/day dosage levels during study weeks 2 to 78, when compared with both control groups (Figs. 4A and 4B). However, with the exception of the 1000 mg/kg/day group, the absolute differences in mean body weights between the control and treated animals during this period were 1 to 2 grams and less than 6% on a percentage basis. Therefore, only at 1000 mg/kg/day were the body weight changes considered to be toxicologically relevant. Average food consumption values through 78 weeks of study were similar between control and treated animals; however, statistical significance was observed for all treated groups with the most frequent significance occurring at the 1000 mg/kg/day dosage level. As was the case with the body weight data, only the differences in food consumption seen at the 1000 mg/kg/day dosage level were considered to be toxicologically relevant. Absolute and relative (to brain weight) kidney weight decreases occurred in male mice at the 250 and 1000 mg/kg/day dosage levels. This decrease in kidney weights followed the decrease in body weights at the high-dose level and no microscopic changes were observed in either case. Therefore, these organ weight differences were not considered to be a direct effect of treatment. Absolute and relative (to body weight and/or brain weight) liver weight increases were seen in both males and females at the 500 and 1000 mg/kg/day dosage levels. These increased liver weights were considered to reflect an adaptive increase in microsomal enzymes since there were no corroborative microscopic findings.
There were no treatment-related microscopic changes in any of the mice when treated groups were compared to controls. A variety of neoplastic and nonneoplastic lesions were observed; however, they were considered to be incidental and unrelated to the test material. The nonneoplastic lesions (Table 5) included various inflammatory lesions in a number of organs, amyloidosis in several tissues and organs, subcapsular cell hyperplasia in the adrenal gland, chronic nephritis, hyperplastic nodules in the liver (more common in males), lymphoid or reticuloendothelial hyperplasia in spleen, testicular degeneration, dilatation of the urinary bladder (males), ovarian cyst or hematocysts, uterine cystic glandular hyperplasia, and other lesions. Frequently occurring neoplastic lesions included malignant lymphoma, hepatocellular adenomas and carcinomas (most common in males), and alveolar/bronchiolar adenomas. Neoplasms occurring only sporadically in the various groups included adrenal pheochromocytoma, Harderian gland cystadenoma, renal adenoma, hepatic hemangioma, mammary adenocarcinoma, pituitary adenoma, uterine leiomyoma, and leiomyosarcoma and other neoplasms.
Dog Chronic Toxicity Study
All dogs survived the one-year chronic toxicity study. Emesis occurred among dogs in all groups including controls, but, along with ptyalism, was observed more frequently for dogs in the 400 mg/kg/day dosage group. Ataxia, tremors, abnormal head movements and convulsions also were observed in one male dog in the 400 mg/kg/day dosage group. The clinical findings for this dog generally were observed within 30 minutes after dosing and were observed on nine occasions over a five-month period during the study. Because of the temporal relationship to dose administration, these clinical signs were considered to be treatment-related. Tremors also were ob- Note. DOS ϭ died on study; SAC ϭ scheduled sacrifice; ٩ ϭ number of animals examined.
served on one or two occasions in one other male dog and in one female dog in the 400 mg/kg/day dosage group, and in one female dog in the 100 mg/kg/day dosage group. Tremors for these three animals generally occurred in the morning prior to dose administration. An additional female dog in the 100 mg/kg/day dosage group was observed with tremors on 11 occasions during a six-week period in the middle of the study. During this same period, the dog was also noted to have decreased activity, to avoid food, to lose body weight, and/or to be in estrus. Since the tremors generally occurred prior to dose administration, and because tremors is not an uncommon finding in control dogs, the tremors observed in these four dogs were not considered to be related to treatment. The parameters of ophthalmology (conducted pretest and at study termination), physical examinations (conducted pretest and during study months 3, 6, 9 and 12), urinalysis (conducted pretest and during study months 6 and 12), organ weights, and gross pathology were unaffected by treatment. Decreases were observed in body weight for male and female dogs in the 400 mg/kg/day dosage group (Figs. 5A and 5B) and food consumption was decreased during the initial few weeks of the study for males and females in the 400 mg/kg/day dosage group (data not presented). Clinical chemistry evaluations (conducted pretest and during study months 6 and 12) revealed a few treatment-related hematological and biochemical changes in the animals in the 400 mg/kg/day dosage group. Hemoglobin and hematocrit values were slightly reduced in males and females at both the 6-and 12-month intervals of analysis; platelet counts were significantly increased ( p Ͻ 0.05) in females at both intervals of analysis (Table 6 ). Alkaline phosphatase activity was increased in males at both the 6-and 12-month intervals of analysis; a statistically significant decrease in cholesterol was observed in males at both intervals of analysis and in the females at the 6-month interval of analysis only; two of the four male dogs had increased potassium levels at the 6-month interval of analysis (Table 7) . There were no treatment-related hematological or biochemical changes at the two lower-dosage levels. The mean liver/body weight ratios of the 30 mg/kg/day and the 100 mg/kg/day males were significantly lower ( p Յ 0.05) than those of the control group. Because a dose response was not evident and because the weight changes were not associated with absolute organ weights or with gross or microscopic changes in the liver, these differences in liverto-body-weight changes were not considered to be related to the administration of the test substance. No significant differences in organ weights were present in the females.
There were no microscopic findings that were considered to be related to the administration of the test substance. A small number of nonneoplastic findings were evident in this study. Several of these were observed in various dose groups, including controls (Table 8) . These included multifocal mineralization of the renal medulla, cysts in the parathyroid and pituitary, congestion of the spleen, and mineralization of the stomach mucosa (cardia and fundus). Other nonneoplastic findings observed in the study included brown pigment in the mandibular lymph node and uterine hyperplasia. Brown pigment (probably hemosiderin) was present in the mandibular lymph node in increased incidence in the treated males (0/4 in the controls, 1/4 in the 30 mg/kg/day group, 2/4 in the 100 mg/kg/day group, 3/4 in the 400 mg/kg/day group). Only very small amounts of pigment were present and no biological significance was attached to this finding. Hyperplasia of the uterus occurred only in treated females (0/4 in the controls, 0/4 in the 30 mg/kg/day group, 1/4 in the 100 mg/kg/day group, 3/4 in the 400 mg/kg/day group). This is considered to be related to normal hormonal physiological variation and not to the administration of the test material. No neoplastic findings were seen in either male or female animals. 
DISCUSSION AND CONCLUSIONS
The objectives of these studies were to evaluate the potential for DEET to produce chronic toxicity and/or oncogenicity when administered orally at the maximum tolerated dose in the rat, mouse and dog, and to define no-effect levels (for all effects) observed in the higher-dosage groups.
In the two-year feeding study conducted in rats, treatment-related effects in the form of depressed body weights and food consumption and slight increases in serum cholesterol were observed in females at the high-dose level (400 mg/kg/day). There were no other treatment-related changes observed in the study. Therefore, the no-effect level in this study was 100 mg/kg/day. In the 18-month feeding study conducted in mice, the only treatment-related effect was a slight decrease in body weight and food consumption at the highest dose level (1000 mg/kg/day) in both males and females. Therefore, the no-effect level in this study was 500 mg/kg/day. In the one-year chronic toxicity study in dogs, an increased incidence of emesis and ptyalism, decreases in body weight and food consumption and changes in several clinical pathology parameters were observed at 400 mg/kg/ day. In addition, ataxia, tremors, abnormal head movements and convulsions were observed in one male dog in the 400 mg/kg/day dosage group. The no-effect level established in this study was 100 mg/kg/day. The general lack of targetorgan toxicity in these studies was not a result of inadequate bioavailability of DEET. Previous studies showed that DEET is rapidly absorbed following oral administration in rats and dogs and distributes to major organs and tissues (Schoenig et al., 1996; Osimitz et al., 1997) .
Published genotoxicity studies support the interpretation of a lack of carcinogenic potential from DEET exposure. DEET did not induce reverse mutations in five strains of S. typhimurium with or without S9 activation and did not induce gene conversions in S. cerevisiae without activation (U.S. EPA, 1980). DEET also was negative for mutagenicity in the bacterial plate assay (Ficsor and Nii Lo Piccolo, 1972) and in a dominant lethal assay conducted in mice at a single oral dose of 600 mg/kg (Swentzel, 1977) . The following unpublished studies sponsored by the DEET Joint Venture also showed uniformly negative results. In an Ames test with a confirmatory assay, no evidence of mutagenicity was noted, with or without metabolic activation (San and Schadly, 1989) . A study of chromosome abberations in Chinese hamster ovary cells showed no increase in chromosomal abberations with or without metabolic activa- (Putman and Morris, 1989) . There was no evidence of an increase in unscheduled DNA synthesis in an unscheduled-DNA-synthesis assay in rat primary hepatocytes with a confirmatory assay (Curren, 1989) .
The long-term toxicity studies presented in the open literature, although pre-GLP and somewhat deficient in achieving acceptable methodological standards, provide some relevant information supporting the conclusions of a lack of target organ toxicity and carcinogenicity. In one dietary study, male and female rats were administered DEET at concentrations of 0.01, 0.05, 0.1, 0.5, and 1.0% for approximately 200 days (Ambrose et al., 1959) . Rats administered 1.0% DEET in diet showed a slight decrease in body weight gain unrelated to food consumption. At the same dietary concentration, some statistically significant increases in organ/body weight ratios were observed for the testes, liver, spleen and kidneys; however, no confirmatory gross or histopathologic changes were observed. In a dermal carcinogenicity study, mice and rabbits were treated cutaneously with approximately 1, 10, or 20 mg DEET in acetone twice a week for life (40 to 120 weeks for mice; 20 to 80 weeks for rabbits) (Stenbaeck, 1977) . No treatmentrelated increase in tumors was observed in these studies. In conclusion, DEET administration did not affect survival or the incidence of tumors in the three chronic studies that are the subject of this manuscript. In addition, no clear evidence of target organ toxicity was observed. In rats and mice, toxicity at the higher dose levels was manifested mainly in the form of decreases in body weight and food consumption. In dogs, a number of changes in clinical pathology in addition to depressions in body weight and food consumption were observed at the highest dose level. One dog in the high-dose group also exhibited clinical signs indicative of acute neurotoxicity. No correlative pathologic changes were observed in the central or peripheral nervous system tissues. These findings are consistent with those from acute and chronic neurotoxicity studies conducted in rats (Schoenig et al., 1993) . In the latter studies, increased response time to heat stimulus and decreased motor activity were observed at a dose level of 500 mg/kg following acute exposure, and an increase in motor activity was observed at a dose level of Ϸ 250 mg/kg/day following chronic exposure. However, detailed microscopic evaluations of the central and peripheral nerve tissues did not reveal any morphologic findings related to treatment. The highest no-observed-effect levels (NOELs) for rats, mice and dogs were determined to be 100, 500, and 100 mg/kg/day, respectively.
